Globavir

Established in 2011, Globavir is a biopharmaceutical company focused on developing therapeutics and diagnostics for infectious diseases. The company was co-founded by Shalabh Gupta and Vijay Pande. Dr. Gupta, who also serves as President and CEO, has a background as a physician and faculty member at NYU Medical Center, with an MD from JIPMER in India and an MPA in Health Finance from NYU. His experience includes roles at Genentech and UBS.

Globavir's business model centers on the rapid development of treatments by repurposing already FDA-approved drugs, utilizing the 505(b)(2) regulatory pathway to expedite the process. The company's initial focus was on therapies and diagnostic tests for dengue fever, a mosquito-borne virus affecting millions annually. Its platform discovery technologies have also been used to identify potential treatments for a range of other viral infections, including Ebola, West Nile, Chikungunya, and Japanese Encephalitis, as well as applications in oncology.

The company's primary therapeutic candidate, GBV-006, is a combination of two existing FDA-approved drugs aimed at treating dengue fever. In diagnostics, Globavir developed the PanGlob™ Dengue detection technology, a platform licensed from Stanford University. This technology led to a significant milestone in October 2016, when Globavir entered into a licensing agreement with Bio-Rad Laboratories for the use of its dengue detection technology. The diagnostic kits have received CE-mark approval for marketing globally. According to some reports, the company is no longer in business as of late 2024.

Keywords: biopharmaceutical, infectious disease therapeutics, diagnostics, dengue fever, drug repurposing, 505(b)(2) pathway, antiviral, oncology, viral detection, CE-mark, PanGlob, GBV-006, Shalabh Gupta, Bio-Rad, West Nile virus, Chikungunya, Ebola virus, therapeutics development, clinical diagnostics, life sciences